STAAR Surgical Company

STAAR Surgical Company

STAA·NASDAQ

$29.33

+2.9%
HealthcareMedical - Instruments & Supplies

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

At a Glance

Live Snapshot
Market Cap$1.46B
EPS-1.6200
P/E Ratio-18.10
Earnings Date08/05/2026
-11.24%
Return on Invested Capital
295%
3Y-209.0%
5Y-612.0%
10Y-55.0%
-23.37%
Return on Equity
360%
3Y-298.0%
5Y-880.0%
10Y-27.0%
-17.43%
Return on Assets
339%
3Y-284.0%
5Y-859.0%
10Y-6.0%
STAAR Surgical Company

STAAR Surgical Company Management Team

STAA · NASDAQ
MT

Mr. Thomas G. Frinzi

Advisor

Compensation

$821,219

Born 1956(Age 70)
male
DM

Dr. Magda Michna Ph.D.

Chief Development Officer and Chief Clinical, Regulatory & Medical Affairs Officer

Compensation

$569,734

MS

Mr. Stephen C. Farrell CFA

Chief Executive Officer & Director

Compensation

$115,000

Born 1965(Age 61)
male
MN

Ms. Nancy Sabin

Chief Marketing Officer

female
DS

Dr. Scott D. Barnes M.D.

Chief Medical Officer

Compensation

$691,149

Born 1963(Age 63)
MD

Ms. Deborah J. Andrews

Interim Chief Financial Officer

Compensation

$755,300

Born 1957(Age 69)
female
MW

Mr. Warren Foust

President & Chief Operating Officer

Compensation

$595,869

Born 1976(Age 50)
male
MJ

Mr. James Francese

Senior Vice President of Commercial Operations - North America & APAC

Compensation

$755,647

Born 1964(Age 62)
male
MN

Mr. Nathaniel B. Sisitsky Esq.

Senior Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

Compensation

$486,974

Born 1974(Age 52)
male
MB

Mr. Brian Moore

Vice President of Investor Relations & Corporate Development

male
staa

STAAR Surgical Company Insider Positioning

STAA · NASDAQ

During the last 12 months, insiders have purchased $28.78M worth of STAA shares, with no selling activity reported.

3 Months

Bought

316.0K

5.88M

Sold

0

0.00

Net Activity

+5.9M

+$5.88M

3-6 Months

Bought

30.7K

677.22K

Sold

0

0.00

Net Activity

+677K

+$677K

6-9 Months

Bought

797.5K

22.22M

Sold

0

0.00

Net Activity

+22.2M

+$22.22M

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
BPL

Broadwood Partners, L.P.

Director, 10 Percent Owner:

1.1M shares4 transactions

$28.78M

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $28.78M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Recent Trend (3 Months)

$5.88M

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

High Buying

1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.

SEC Filings

STAA - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

May 04, 2026
May 01, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 24, 2025
April 24, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 24, 2024
June 20, 2024
2024
DEF 14A

DEF 14A

N/A

April 26, 2023
April 26, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 29, 2022
June 16, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 30, 2021
June 24, 2021
2021
DEF 14A

DEF 14A 2020

N/A

June 08, 2020
July 30, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 29, 2019
June 20, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 26, 2018
June 14, 2018
2018
DEF 14A

DEF 14A 2017

N/A

May 01, 2017
June 13, 2017
2017
Showing 1 to 10 of 32 filings